ALVO · Alvotech

0001171843-26-004991

Summary

Alvotech announced the successful closure of FDA inspection at its Reykjavik facility with a VAI classification, an important regulatory milestone.

Key takeaways

FDA closed May 2026 inspection at Alvotech's Reykjavik facility; classification VAI indicates voluntary actions.
CEO emphasized strengthened quality systems; Alvotech continues working with FDA on BLA approvals.
Regulatory progress supports biosimilar pipeline including AVT05, AVT06, and AVT16 submissions.

Full analysis

The FDA's VAI classification reflects Alvotech's remediation efforts following prior observations. This positive outcome could facilitate progress on pending BLA submissions for biosimilars AVT05 (golimumab), AVT06 (aflibercept), and AVT16 (vedolizumab), potentially accelerating time to market for these candidates.